chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Vision blurred, Visual impairment, Weight decreased
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: 5-hydroxyindolacetic acid in urine increased, Alanine aminotransferase normal, Blood albumin normal, Blood creatinine decreased, Blood glucose normal
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Blood immunoglobulin G, Blood urea decreased, Creatinine renal clearance increased, Cytomegalovirus infection, Depression
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Fatigue, Laboratory test, Protein total normal, Serum serotonin increased
Clinical narrative: reactivation CMV infection, chronic fatigue, depression/anxiety
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Diarrhoea, Headache, Pain, Postmenopausal haemorrhage, Pyrexia
Clinical narrative: I experienced a huge knot in my arm, redness, swelling, fever, chills, nausea, diarrhea and postmenopausal.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Diarrhoea, Erythema, Nausea, Nodule
Clinical narrative: I experienced a huge knot in my arm, redness, swelling, fever, chills, nausea, diarrhea and postmenopausal.
Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Postmenopause, Pyrexia, Swelling
Clinical narrative: I experienced a huge knot in my arm, redness, swelling, fever, chills, nausea, diarrhea and postmenopausal.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Contusion, Hypoaesthesia, Neck pain
Clinical narrative: Numbness in fingers; bruising on back and shoulder; sharp dull pain sharp stabbing pain/a variety of other different pains; extreme weakness; confusion; loss of grip; This is a spontaneous report from a contactable consumer. This 44-year-old female consumer (patient) reported for herself that. A 44-year-old female patient received BNT162B2 (formulation: Solution for injection, Lot Number: Fdo809), via an unspecified route of administration, administered in arm left, on 18Oct2021 (at the age of 44 years) as DOSE 3 (booster), SINGLE, and received BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 18Oct2021 administered in arm left, as DOSE NUMBER UNKOWN, SINGLE for COVID-19 immunisation. it was reported that the patient was not a pregnant at the time of vaccination. The patient medical history included Depression and adhd from an unknown date and unknown if ongoing. Concomitant medications included: LAMOTRIGINE on unspecified date. The patient previously received historical vaccine BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 04Jan2021 administered in arm left, as DOSE 1, SINGLE, received second dose BNT162B2 (formulation: Solution for injection, Lot Number: El3298), via an unspecified route of administration, administered in arm left, on 25Jan2021 administered in arm left, as DOSE 1, SINGLE, and for COVID-19 immunisation. The patient Past drug history included the Cipro, reactions and known allergies: Cipro and other historical vaccine received Flu shot (other vaccine 4weeks details, other vaccine 4weeks product=Flu shot, other vaccine 4weeks vaccine location=L arm). The patient experienced Numbness in fingers, bruising on back and shoulder, sharp dull pain sharp stabbing pain/a variety of other different pains, extreme weakness, confusion and loss of grip all from on 19Oct2021. Therapeutic measures were taken as a result of hypoaesthesia, contusion, pain, asthenia, confusional state, grip strength decreased. The clinical outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Back pain, Condition aggravated, Contusion, Headache
Clinical narrative: Numbness in fingers; bruising on back and shoulder; sharp dull pain sharp stabbing pain/a variety of other different pains; extreme weakness; confusion; loss of grip; This is a spontaneous report from a contactable consumer. This 44-year-old female consumer (patient) reported for herself that. A 44-year-old female patient received BNT162B2 (formulation: Solution for injection, Lot Number: Fdo809), via an unspecified route of administration, administered in arm left, on 18Oct2021 (at the age of 44 years) as DOSE 3 (booster), SINGLE, and received BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 18Oct2021 administered in arm left, as DOSE NUMBER UNKOWN, SINGLE for COVID-19 immunisation. it was reported that the patient was not a pregnant at the time of vaccination. The patient medical history included Depression and adhd from an unknown date and unknown if ongoing. Concomitant medications included: LAMOTRIGINE on unspecified date. The patient previously received historical vaccine BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 04Jan2021 administered in arm left, as DOSE 1, SINGLE, received second dose BNT162B2 (formulation: Solution for injection, Lot Number: El3298), via an unspecified route of administration, administered in arm left, on 25Jan2021 administered in arm left, as DOSE 1, SINGLE, and for COVID-19 immunisation. The patient Past drug history included the Cipro, reactions and known allergies: Cipro and other historical vaccine received Flu shot (other vaccine 4weeks details, other vaccine 4weeks product=Flu shot, other vaccine 4weeks vaccine location=L arm). The patient experienced Numbness in fingers, bruising on back and shoulder, sharp dull pain sharp stabbing pain/a variety of other different pains, extreme weakness, confusion and loss of grip all from on 19Oct2021. Therapeutic measures were taken as a result of hypoaesthesia, contusion, pain, asthenia, confusional state, grip strength decreased. The clinical outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hypoaesthesia, Magnetic resonance imaging normal, Movement disorder, Muscle spasms, Neck pain
Clinical narrative: Numbness in fingers; bruising on back and shoulder; sharp dull pain sharp stabbing pain/a variety of other different pains; extreme weakness; confusion; loss of grip; This is a spontaneous report from a contactable consumer. This 44-year-old female consumer (patient) reported for herself that. A 44-year-old female patient received BNT162B2 (formulation: Solution for injection, Lot Number: Fdo809), via an unspecified route of administration, administered in arm left, on 18Oct2021 (at the age of 44 years) as DOSE 3 (booster), SINGLE, and received BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 18Oct2021 administered in arm left, as DOSE NUMBER UNKOWN, SINGLE for COVID-19 immunisation. it was reported that the patient was not a pregnant at the time of vaccination. The patient medical history included Depression and adhd from an unknown date and unknown if ongoing. Concomitant medications included: LAMOTRIGINE on unspecified date. The patient previously received historical vaccine BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 04Jan2021 administered in arm left, as DOSE 1, SINGLE, received second dose BNT162B2 (formulation: Solution for injection, Lot Number: El3298), via an unspecified route of administration, administered in arm left, on 25Jan2021 administered in arm left, as DOSE 1, SINGLE, and for COVID-19 immunisation. The patient Past drug history included the Cipro, reactions and known allergies: Cipro and other historical vaccine received Flu shot (other vaccine 4weeks details, other vaccine 4weeks product=Flu shot, other vaccine 4weeks vaccine location=L arm). The patient experienced Numbness in fingers, bruising on back and shoulder, sharp dull pain sharp stabbing pain/a variety of other different pains, extreme weakness, confusion and loss of grip all from on 19Oct2021. Therapeutic measures were taken as a result of hypoaesthesia, contusion, pain, asthenia, confusional state, grip strength decreased. The clinical outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Neurological examination normal, Peripheral swelling
Clinical narrative: Numbness in fingers; bruising on back and shoulder; sharp dull pain sharp stabbing pain/a variety of other different pains; extreme weakness; confusion; loss of grip; This is a spontaneous report from a contactable consumer. This 44-year-old female consumer (patient) reported for herself that. A 44-year-old female patient received BNT162B2 (formulation: Solution for injection, Lot Number: Fdo809), via an unspecified route of administration, administered in arm left, on 18Oct2021 (at the age of 44 years) as DOSE 3 (booster), SINGLE, and received BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 18Oct2021 administered in arm left, as DOSE NUMBER UNKOWN, SINGLE for COVID-19 immunisation. it was reported that the patient was not a pregnant at the time of vaccination. The patient medical history included Depression and adhd from an unknown date and unknown if ongoing. Concomitant medications included: LAMOTRIGINE on unspecified date. The patient previously received historical vaccine BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 04Jan2021 administered in arm left, as DOSE 1, SINGLE, received second dose BNT162B2 (formulation: Solution for injection, Lot Number: El3298), via an unspecified route of administration, administered in arm left, on 25Jan2021 administered in arm left, as DOSE 1, SINGLE, and for COVID-19 immunisation. The patient Past drug history included the Cipro, reactions and known allergies: Cipro and other historical vaccine received Flu shot (other vaccine 4weeks details, other vaccine 4weeks product=Flu shot, other vaccine 4weeks vaccine location=L arm). The patient experienced Numbness in fingers, bruising on back and shoulder, sharp dull pain sharp stabbing pain/a variety of other different pains, extreme weakness, confusion and loss of grip all from on 19Oct2021. Therapeutic measures were taken as a result of hypoaesthesia, contusion, pain, asthenia, confusional state, grip strength decreased. The clinical outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, Confusional state, Contusion, Grip strength decreased, Hypoaesthesia
Clinical narrative: Numbness in fingers; bruising on back and shoulder; sharp dull pain sharp stabbing pain/a variety of other different pains; extreme weakness; confusion; loss of grip; This is a spontaneous report from a contactable consumer. This 44-year-old female consumer (patient) reported for herself that. A 44-year-old female patient received BNT162B2 (formulation: Solution for injection, Lot Number: Fdo809), via an unspecified route of administration, administered in arm left, on 18Oct2021 (at the age of 44 years) as DOSE 3 (booster), SINGLE, and received BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 18Oct2021 administered in arm left, as DOSE NUMBER UNKOWN, SINGLE for COVID-19 immunisation. it was reported that the patient was not a pregnant at the time of vaccination. The patient medical history included Depression and adhd from an unknown date and unknown if ongoing. Concomitant medications included: LAMOTRIGINE on unspecified date. The patient previously received historical vaccine BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 04Jan2021 administered in arm left, as DOSE 1, SINGLE, received second dose BNT162B2 (formulation: Solution for injection, Lot Number: El3298), via an unspecified route of administration, administered in arm left, on 25Jan2021 administered in arm left, as DOSE 1, SINGLE, and for COVID-19 immunisation. The patient Past drug history included the Cipro, reactions and known allergies: Cipro and other historical vaccine received Flu shot (other vaccine 4weeks details, other vaccine 4weeks product=Flu shot, other vaccine 4weeks vaccine location=L arm). The patient experienced Numbness in fingers, bruising on back and shoulder, sharp dull pain sharp stabbing pain/a variety of other different pains, extreme weakness, confusion and loss of grip all from on 19Oct2021. Therapeutic measures were taken as a result of hypoaesthesia, contusion, pain, asthenia, confusional state, grip strength decreased. The clinical outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pain
Clinical narrative: Numbness in fingers; bruising on back and shoulder; sharp dull pain sharp stabbing pain/a variety of other different pains; extreme weakness; confusion; loss of grip; This is a spontaneous report from a contactable consumer. This 44-year-old female consumer (patient) reported for herself that. A 44-year-old female patient received BNT162B2 (formulation: Solution for injection, Lot Number: Fdo809), via an unspecified route of administration, administered in arm left, on 18Oct2021 (at the age of 44 years) as DOSE 3 (booster), SINGLE, and received BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 18Oct2021 administered in arm left, as DOSE NUMBER UNKOWN, SINGLE for COVID-19 immunisation. it was reported that the patient was not a pregnant at the time of vaccination. The patient medical history included Depression and adhd from an unknown date and unknown if ongoing. Concomitant medications included: LAMOTRIGINE on unspecified date. The patient previously received historical vaccine BNT162B2 (formulation: Solution for injection, Lot Number: Elo142), via an unspecified route of administration, administered in arm left, on 04Jan2021 administered in arm left, as DOSE 1, SINGLE, received second dose BNT162B2 (formulation: Solution for injection, Lot Number: El3298), via an unspecified route of administration, administered in arm left, on 25Jan2021 administered in arm left, as DOSE 1, SINGLE, and for COVID-19 immunisation. The patient Past drug history included the Cipro, reactions and known allergies: Cipro and other historical vaccine received Flu shot (other vaccine 4weeks details, other vaccine 4weeks product=Flu shot, other vaccine 4weeks vaccine location=L arm). The patient experienced Numbness in fingers, bruising on back and shoulder, sharp dull pain sharp stabbing pain/a variety of other different pains, extreme weakness, confusion and loss of grip all from on 19Oct2021. Therapeutic measures were taken as a result of hypoaesthesia, contusion, pain, asthenia, confusional state, grip strength decreased. The clinical outcome of the events was not recovered.  Follow-up attempts are completed. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Cardiac flutter
Clinical narrative: fluttering; electrical problem that is just continuing to get worse; fluttering/electrical problem that is just continuing to get worse; fluttering, quizzing in throat; BP high one min and extreme low the next; This is a spontaneous report received from a contactable reporter (Consumer). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular, administered in arm left, administration date 09Sep2021 (Lot number: FE3592) as dose 2, single for covid-19 immunisation. Relevant medical history included: "increase my BP" (unspecified if ongoing); "Cholesterol" (ongoing); "BP" (ongoing); "fluttering", start date: 2020 (unspecified if ongoing), notes: after mange test (cardiac Cath -Echo - heart monitor); "imbalances/electrical prob" (unspecified if ongoing), notes: after mange test (cardiac Cath -Echo - heart monitor). Concomitant medications included: ROSUVASTATIN taken for blood cholesterol abnormal, start date: 2020 (ongoing); METOPROLOL taken for blood pressure abnormal, start date: 2020 (ongoing). Vaccination history included: Bnt162b2 (1st dose, 10:00 AM, Left arm, intramuscular, Batch/Lot number: FC3181), administration date: 19Aug2021, for COVID-19 immunization, reaction(s): "flutters", "flutters". The following information was reported: CARDIAC FLUTTER (medically significant), outcome "not recovered", described as "fluttering"; ARRHYTHMIA (medically significant), outcome "not recovered", described as "electrical problem that is just continuing to get worse"; DISEASE RECURRENCE (medically significant), outcome "not recovered", described as "fluttering/electrical problem that is just continuing to get worse"; OROPHARYNGEAL DISCOMFORT (non-serious), outcome "not recovered", described as "fluttering, quizzing in throat"; BLOOD PRESSURE FLUCTUATION (non-serious), outcome "not recovered", described as "BP high one min and extreme low the next". The patient underwent the following laboratory tests and procedures: blood pressure measurement: high. Therapeutic measures were taken as a result of cardiac flutter, arrhythmia, disease recurrence, oropharyngeal discomfort, blood pressure fluctuation.  Clinical course: After the 2nd Dose of Pfizer the fluttering, quizzing in throat refered along with BP high one min and extreme low the next. The doctor put patient on 25 mg night 12.5 mg morning on the metoprolol. The symptoms continued - the doctor now said patient will have to see an electrophysiologist and possibly need a cardia ablation to resolve the electrical problem that is just continuing to get worse.  No follow-up attempts are possible. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Arrhythmia, Blood pressure fluctuation, Blood pressure measurement, Cardiac flutter, Disease recurrence
Clinical narrative: fluttering; electrical problem that is just continuing to get worse; fluttering/electrical problem that is just continuing to get worse; fluttering, quizzing in throat; BP high one min and extreme low the next; This is a spontaneous report received from a contactable reporter (Consumer). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular, administered in arm left, administration date 09Sep2021 (Lot number: FE3592) as dose 2, single for covid-19 immunisation. Relevant medical history included: "increase my BP" (unspecified if ongoing); "Cholesterol" (ongoing); "BP" (ongoing); "fluttering", start date: 2020 (unspecified if ongoing), notes: after mange test (cardiac Cath -Echo - heart monitor); "imbalances/electrical prob" (unspecified if ongoing), notes: after mange test (cardiac Cath -Echo - heart monitor). Concomitant medications included: ROSUVASTATIN taken for blood cholesterol abnormal, start date: 2020 (ongoing); METOPROLOL taken for blood pressure abnormal, start date: 2020 (ongoing). Vaccination history included: Bnt162b2 (1st dose, 10:00 AM, Left arm, intramuscular, Batch/Lot number: FC3181), administration date: 19Aug2021, for COVID-19 immunization, reaction(s): "flutters", "flutters". The following information was reported: CARDIAC FLUTTER (medically significant), outcome "not recovered", described as "fluttering"; ARRHYTHMIA (medically significant), outcome "not recovered", described as "electrical problem that is just continuing to get worse"; DISEASE RECURRENCE (medically significant), outcome "not recovered", described as "fluttering/electrical problem that is just continuing to get worse"; OROPHARYNGEAL DISCOMFORT (non-serious), outcome "not recovered", described as "fluttering, quizzing in throat"; BLOOD PRESSURE FLUCTUATION (non-serious), outcome "not recovered", described as "BP high one min and extreme low the next". The patient underwent the following laboratory tests and procedures: blood pressure measurement: high. Therapeutic measures were taken as a result of cardiac flutter, arrhythmia, disease recurrence, oropharyngeal discomfort, blood pressure fluctuation.  Clinical course: After the 2nd Dose of Pfizer the fluttering, quizzing in throat refered along with BP high one min and extreme low the next. The doctor put patient on 25 mg night 12.5 mg morning on the metoprolol. The symptoms continued - the doctor now said patient will have to see an electrophysiologist and possibly need a cardia ablation to resolve the electrical problem that is just continuing to get worse.  No follow-up attempts are possible. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Oropharyngeal discomfort
Clinical narrative: fluttering; electrical problem that is just continuing to get worse; fluttering/electrical problem that is just continuing to get worse; fluttering, quizzing in throat; BP high one min and extreme low the next; This is a spontaneous report received from a contactable reporter (Consumer). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular, administered in arm left, administration date 09Sep2021 (Lot number: FE3592) as dose 2, single for covid-19 immunisation. Relevant medical history included: "increase my BP" (unspecified if ongoing); "Cholesterol" (ongoing); "BP" (ongoing); "fluttering", start date: 2020 (unspecified if ongoing), notes: after mange test (cardiac Cath -Echo - heart monitor); "imbalances/electrical prob" (unspecified if ongoing), notes: after mange test (cardiac Cath -Echo - heart monitor). Concomitant medications included: ROSUVASTATIN taken for blood cholesterol abnormal, start date: 2020 (ongoing); METOPROLOL taken for blood pressure abnormal, start date: 2020 (ongoing). Vaccination history included: Bnt162b2 (1st dose, 10:00 AM, Left arm, intramuscular, Batch/Lot number: FC3181), administration date: 19Aug2021, for COVID-19 immunization, reaction(s): "flutters", "flutters". The following information was reported: CARDIAC FLUTTER (medically significant), outcome "not recovered", described as "fluttering"; ARRHYTHMIA (medically significant), outcome "not recovered", described as "electrical problem that is just continuing to get worse"; DISEASE RECURRENCE (medically significant), outcome "not recovered", described as "fluttering/electrical problem that is just continuing to get worse"; OROPHARYNGEAL DISCOMFORT (non-serious), outcome "not recovered", described as "fluttering, quizzing in throat"; BLOOD PRESSURE FLUCTUATION (non-serious), outcome "not recovered", described as "BP high one min and extreme low the next". The patient underwent the following laboratory tests and procedures: blood pressure measurement: high. Therapeutic measures were taken as a result of cardiac flutter, arrhythmia, disease recurrence, oropharyngeal discomfort, blood pressure fluctuation.  Clinical course: After the 2nd Dose of Pfizer the fluttering, quizzing in throat refered along with BP high one min and extreme low the next. The doctor put patient on 25 mg night 12.5 mg morning on the metoprolol. The symptoms continued - the doctor now said patient will have to see an electrophysiologist and possibly need a cardia ablation to resolve the electrical problem that is just continuing to get worse.  No follow-up attempts are possible. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Amnesia, Balance disorder, Bradykinesia, Headache, Magnetic resonance imaging normal
Clinical narrative: This is a spontaneous report received from a contactable reporter (consumer). The reporter is the patient. A 59 year-old female patient received 3rd dose of bnt162b2 (BNT162B2), administered in arm right, administration date 12Oct2021 (Lot number: 30145BA, Expiration Date: 30Nov2021) at the age of 59 years as booster single for covid-19 immunisation. Relevant medical history included: "Cerebrovascular accident", start date: 2013 (ongoing), notes: Stroke, Stated that it was a thalamic stroke that was much different than what most people know about, Stated that when she had the stroke it affected one or more parts of her body her right hand and right side of her face. Stated that it is on fire constantly and will affect her the rest of her life; "car wreck", start date: 26Jun2021 (unspecified if ongoing). The patient took concomitant medications. Patient stated that she had a stroke and is on 10 pills.  Vaccination history included: Bnt162b2 (dose number: 1, first dose: 07Mar2021 , lot# EN6199 , Exp date: Jun2021), administration date: 07Mar2021, when the patient was 58 years old, for COVID-19 immunization; Bnt162b2 (dose number: 2, second dose: 07Apr2021, lot# EP6955 , Exp. date: 30Jun2021.), administration date: 07Apr2021, when the patient was 58 years old, for COVID-19 immunization. The following information was reported: multiple sclerosis (medically significant) with onset 02Nov2021, outcome "not recovered", described as "Multiple sclerosis"; infectious mononucleosis (non-serious) with onset 02Nov2021, outcome "recovering", described as "stated that it reacted her mononucleosis". Additional Information: No investigation Assessment. Patient reported that the booster shot gave her multiple sclerosis (MS).  Patient stated that she thought this was because of a car wreck that she had on 26Jun2021 which was before the booster.   She had not been to a neurologist yet. Patient stated that there was nothing that they can do for mononucleosis and stated that she just sleeps a lot.   Follow-up attempts are completed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Protein total increased, Speech disorder, Vision blurred
Clinical narrative: This is a spontaneous report received from a contactable reporter (consumer). The reporter is the patient. A 59 year-old female patient received 3rd dose of bnt162b2 (BNT162B2), administered in arm right, administration date 12Oct2021 (Lot number: 30145BA, Expiration Date: 30Nov2021) at the age of 59 years as booster single for covid-19 immunisation. Relevant medical history included: "Cerebrovascular accident", start date: 2013 (ongoing), notes: Stroke, Stated that it was a thalamic stroke that was much different than what most people know about, Stated that when she had the stroke it affected one or more parts of her body her right hand and right side of her face. Stated that it is on fire constantly and will affect her the rest of her life; "car wreck", start date: 26Jun2021 (unspecified if ongoing). The patient took concomitant medications. Patient stated that she had a stroke and is on 10 pills.  Vaccination history included: Bnt162b2 (dose number: 1, first dose: 07Mar2021 , lot# EN6199 , Exp date: Jun2021), administration date: 07Mar2021, when the patient was 58 years old, for COVID-19 immunization; Bnt162b2 (dose number: 2, second dose: 07Apr2021, lot# EP6955 , Exp. date: 30Jun2021.), administration date: 07Apr2021, when the patient was 58 years old, for COVID-19 immunization. The following information was reported: multiple sclerosis (medically significant) with onset 02Nov2021, outcome "not recovered", described as "Multiple sclerosis"; infectious mononucleosis (non-serious) with onset 02Nov2021, outcome "recovering", described as "stated that it reacted her mononucleosis". Additional Information: No investigation Assessment. Patient reported that the booster shot gave her multiple sclerosis (MS).  Patient stated that she thought this was because of a car wreck that she had on 26Jun2021 which was before the booster.   She had not been to a neurologist yet. Patient stated that there was nothing that they can do for mononucleosis and stated that she just sleeps a lot.   Follow-up attempts are completed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Infectious mononucleosis, Multiple sclerosis
Clinical narrative: This is a spontaneous report received from a contactable reporter (consumer). The reporter is the patient. A 59 year-old female patient received 3rd dose of bnt162b2 (BNT162B2), administered in arm right, administration date 12Oct2021 (Lot number: 30145BA, Expiration Date: 30Nov2021) at the age of 59 years as booster single for covid-19 immunisation. Relevant medical history included: "Cerebrovascular accident", start date: 2013 (ongoing), notes: Stroke, Stated that it was a thalamic stroke that was much different than what most people know about, Stated that when she had the stroke it affected one or more parts of her body her right hand and right side of her face. Stated that it is on fire constantly and will affect her the rest of her life; "car wreck", start date: 26Jun2021 (unspecified if ongoing). The patient took concomitant medications. Patient stated that she had a stroke and is on 10 pills.  Vaccination history included: Bnt162b2 (dose number: 1, first dose: 07Mar2021 , lot# EN6199 , Exp date: Jun2021), administration date: 07Mar2021, when the patient was 58 years old, for COVID-19 immunization; Bnt162b2 (dose number: 2, second dose: 07Apr2021, lot# EP6955 , Exp. date: 30Jun2021.), administration date: 07Apr2021, when the patient was 58 years old, for COVID-19 immunization. The following information was reported: multiple sclerosis (medically significant) with onset 02Nov2021, outcome "not recovered", described as "Multiple sclerosis"; infectious mononucleosis (non-serious) with onset 02Nov2021, outcome "recovering", described as "stated that it reacted her mononucleosis". Additional Information: No investigation Assessment. Patient reported that the booster shot gave her multiple sclerosis (MS).  Patient stated that she thought this was because of a car wreck that she had on 26Jun2021 which was before the booster.   She had not been to a neurologist yet. Patient stated that there was nothing that they can do for mononucleosis and stated that she just sleeps a lot.   Follow-up attempts are completed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Acoustic stimulation tests abnormal, Deafness neurosensory, Deafness unilateral, Hypoacusis, Oedema peripheral
Clinical narrative: Noticed ringing and dimished hearing in left ear; Noticed ringing and diminished hearing in left ear; Swelling in left armpit; booster; This is a spontaneous report received from contactable reporter (Consumer or other non HCP) (patient).  A 49-year-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm left, administration date 26Oct2021 14:30 (Lot number: FF2593) at the age of 49 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Ovarian cyst" (unspecified if ongoing); "fibroids" (unspecified if ongoing); "breast cancer" (unspecified if ongoing); "spontaneous pneumothorax" (unspecified if ongoing); "slightly allergic to latex" (unspecified if ongoing); "slightly allergic to nickel" (unspecified if ongoing). Concomitant medications included: EUCRISA; TAMOXIFEN; VITAMIN D3. Vaccination history included: Bnt162b2 (dose brand=Pfizer, lot number=EN6206, administration date=14Mar2021, dose number=2), administration date: 14Mar2021, when the patient was 49 years old, for Covid-19 immunization; Bnt162b2 (dose brand=Pfizer, lot number=EL9267, administration date=21Feb2021, administration time=12:00PM, dose number=1), administration date: 21Feb2021, when the patient was 49 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (disability) with onset 26Oct2021 14:30, outcome "unknown", described as "booster"; SWELLING (disability) with onset 28Oct2021, outcome "not recovered", described as "Swelling in left armpit"; TINNITUS (disability) with onset 07Nov2021, outcome "not recovered", described as "Noticed ringing and diminished hearing in left ear"; HYPOACUSIS (disability) with onset 07Nov2021, outcome "not recovered", described as "Noticed ringing and diminished hearing in left ear". The events "swelling in left armpit", "noticed ringing and diminished hearing in left ear" were evaluated at the physician office visit. Therapeutic measures were taken as a result of swelling, tinnitus, hypoacusis, which the treatment included methylprednisolone 4mg dosepk + steroid injection.  Clinical course: The report was reported as being disability or permanent damage. The patient had no COVID prior vaccination. The patient had no COVID tesy post vaccination.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Noticed ringing and dimished hearing in left ear; Noticed ringing and diminished hearing in left ear; Swelling in left armpit; booster; This is a spontaneous report received from contactable reporter (Consumer or other non HCP) (patient).  A 49-year-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm left, administration date 26Oct2021 14:30 (Lot number: FF2593) at the age of 49 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Ovarian cyst" (unspecified if ongoing); "fibroids" (unspecified if ongoing); "breast cancer" (unspecified if ongoing); "spontaneous pneumothorax" (unspecified if ongoing); "slightly allergic to latex" (unspecified if ongoing); "slightly allergic to nickel" (unspecified if ongoing). Concomitant medications included: EUCRISA; TAMOXIFEN; VITAMIN D3. Vaccination history included: Bnt162b2 (dose brand=Pfizer, lot number=EN6206, administration date=14Mar2021, dose number=2), administration date: 14Mar2021, when the patient was 49 years old, for Covid-19 immunization; Bnt162b2 (dose brand=Pfizer, lot number=EL9267, administration date=21Feb2021, administration time=12:00PM, dose number=1), administration date: 21Feb2021, when the patient was 49 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (disability) with onset 26Oct2021 14:30, outcome "unknown", described as "booster"; SWELLING (disability) with onset 28Oct2021, outcome "not recovered", described as "Swelling in left armpit"; TINNITUS (disability) with onset 07Nov2021, outcome "not recovered", described as "Noticed ringing and diminished hearing in left ear"; HYPOACUSIS (disability) with onset 07Nov2021, outcome "not recovered", described as "Noticed ringing and diminished hearing in left ear". The events "swelling in left armpit", "noticed ringing and diminished hearing in left ear" were evaluated at the physician office visit. Therapeutic measures were taken as a result of swelling, tinnitus, hypoacusis, which the treatment included methylprednisolone 4mg dosepk + steroid injection.  Clinical course: The report was reported as being disability or permanent damage. The patient had no COVID prior vaccination. The patient had no COVID tesy post vaccination.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Hypoacusis, Immunisation, Swelling, Tinnitus
Clinical narrative: Noticed ringing and dimished hearing in left ear; Noticed ringing and diminished hearing in left ear; Swelling in left armpit; booster; This is a spontaneous report received from contactable reporter (Consumer or other non HCP) (patient).  A 49-year-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm left, administration date 26Oct2021 14:30 (Lot number: FF2593) at the age of 49 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Ovarian cyst" (unspecified if ongoing); "fibroids" (unspecified if ongoing); "breast cancer" (unspecified if ongoing); "spontaneous pneumothorax" (unspecified if ongoing); "slightly allergic to latex" (unspecified if ongoing); "slightly allergic to nickel" (unspecified if ongoing). Concomitant medications included: EUCRISA; TAMOXIFEN; VITAMIN D3. Vaccination history included: Bnt162b2 (dose brand=Pfizer, lot number=EN6206, administration date=14Mar2021, dose number=2), administration date: 14Mar2021, when the patient was 49 years old, for Covid-19 immunization; Bnt162b2 (dose brand=Pfizer, lot number=EL9267, administration date=21Feb2021, administration time=12:00PM, dose number=1), administration date: 21Feb2021, when the patient was 49 years old, for Covid-19 immunization. The following information was reported: IMMUNISATION (disability) with onset 26Oct2021 14:30, outcome "unknown", described as "booster"; SWELLING (disability) with onset 28Oct2021, outcome "not recovered", described as "Swelling in left armpit"; TINNITUS (disability) with onset 07Nov2021, outcome "not recovered", described as "Noticed ringing and diminished hearing in left ear"; HYPOACUSIS (disability) with onset 07Nov2021, outcome "not recovered", described as "Noticed ringing and diminished hearing in left ear". The events "swelling in left armpit", "noticed ringing and diminished hearing in left ear" were evaluated at the physician office visit. Therapeutic measures were taken as a result of swelling, tinnitus, hypoacusis, which the treatment included methylprednisolone 4mg dosepk + steroid injection.  Clinical course: The report was reported as being disability or permanent damage. The patient had no COVID prior vaccination. The patient had no COVID tesy post vaccination.
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: Site: Itching at Injection Site-Severe, Site: Redness at Injection Site-Severe
Age: 59.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site erythema, Injection site pruritus
Clinical narrative: Site: Itching at Injection Site-Severe, Site: Redness at Injection Site-Severe
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Biopsy, Gynaecological examination, Heavy menstrual bleeding, Postmenopausal haemorrhage, Smear cervix
Clinical narrative: I experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 28Apr2021 10:15 (Batch/Lot number: unknown) at the age of 52 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Known allergies: food allergies" (unspecified if ongoing), notes: Known allergies: certain food allergies, but they're more, like intolerances. Concomitant medication(s) included: VITAMIN D. Vaccination history included: Bnt162b2 (Dose Number: 1, Location of injection: Arm Right, Vaccine Administration Time: 10:15 AM), administration date: 31Mar2021, when the patient was 51 years old, for COVID-19 Immunization. If other vaccine in four weeks, if covid prior vaccination and if covid tested post vaccination were reported as No. Patient was not pregnant at time of Vaccination. The following information was reported: POSTMENOPAUSAL HAEMORRHAGE (medically significant) with onset 19Jun2021, outcome "recovered" (2021), described as "I experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years". The event "i experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years" was evaluated at the physician office visit. Patient experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years. Her clinic ran multiple tests to rule out cancer and other potential problems before she learned online that other women were experiencing this side effect from the vaccine. After 2 periods, the problem stopped, just as she read online that other women experienced. Event requires visit physician office visit. Therapeutic measures were taken as a result of postmenopausal haemorrhage.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Ultrasound scan
Clinical narrative: I experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 28Apr2021 10:15 (Batch/Lot number: unknown) at the age of 52 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Known allergies: food allergies" (unspecified if ongoing), notes: Known allergies: certain food allergies, but they're more, like intolerances. Concomitant medication(s) included: VITAMIN D. Vaccination history included: Bnt162b2 (Dose Number: 1, Location of injection: Arm Right, Vaccine Administration Time: 10:15 AM), administration date: 31Mar2021, when the patient was 51 years old, for COVID-19 Immunization. If other vaccine in four weeks, if covid prior vaccination and if covid tested post vaccination were reported as No. Patient was not pregnant at time of Vaccination. The following information was reported: POSTMENOPAUSAL HAEMORRHAGE (medically significant) with onset 19Jun2021, outcome "recovered" (2021), described as "I experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years". The event "i experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years" was evaluated at the physician office visit. Patient experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years. Her clinic ran multiple tests to rule out cancer and other potential problems before she learned online that other women were experiencing this side effect from the vaccine. After 2 periods, the problem stopped, just as she read online that other women experienced. Event requires visit physician office visit. Therapeutic measures were taken as a result of postmenopausal haemorrhage.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Age: 52.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Postmenopausal haemorrhage
Clinical narrative: I experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 28Apr2021 10:15 (Batch/Lot number: unknown) at the age of 52 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Known allergies: food allergies" (unspecified if ongoing), notes: Known allergies: certain food allergies, but they're more, like intolerances. Concomitant medication(s) included: VITAMIN D. Vaccination history included: Bnt162b2 (Dose Number: 1, Location of injection: Arm Right, Vaccine Administration Time: 10:15 AM), administration date: 31Mar2021, when the patient was 51 years old, for COVID-19 Immunization. If other vaccine in four weeks, if covid prior vaccination and if covid tested post vaccination were reported as No. Patient was not pregnant at time of Vaccination. The following information was reported: POSTMENOPAUSAL HAEMORRHAGE (medically significant) with onset 19Jun2021, outcome "recovered" (2021), described as "I experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years". The event "i experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years" was evaluated at the physician office visit. Patient experienced post-menopausal vaginal bleeding for 2 months, as heavy (but typical, schedule-wise) periods after being post-menopausal for years. Her clinic ran multiple tests to rule out cancer and other potential problems before she learned online that other women were experiencing this side effect from the vaccine. After 2 periods, the problem stopped, just as she read online that other women experienced. Event requires visit physician office visit. Therapeutic measures were taken as a result of postmenopausal haemorrhage.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Age: 78.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asymptomatic COVID-19, SARS-CoV-2 test positive
Clinical narrative: tested positive for COVID-19 upon admission on 11/20 but remained asyptomatic. Baseline CXR was obtained 11/21 showing pneumonitis but no other acute findings. ID was curbside consulted 11/21 with recommendation to administer monoclonal antibody with Casirivimab-Imdevimab due to age >65, close contact to confirmed COVID-19 positive adult, and due to suspected
Age: 78.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Asymptomatic COVID-19, COVID-19, Chest X-ray abnormal, Exposure to SARS-CoV-2, Pneumonitis
Clinical narrative: tested positive for COVID-19 upon admission on 11/20 but remained asyptomatic. Baseline CXR was obtained 11/21 showing pneumonitis but no other acute findings. ID was curbside consulted 11/21 with recommendation to administer monoclonal antibody with Casirivimab-Imdevimab due to age >65, close contact to confirmed COVID-19 positive adult, and due to suspected
Age: 78.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: tested positive for COVID-19 upon admission on 11/20 but remained asyptomatic. Baseline CXR was obtained 11/21 showing pneumonitis but no other acute findings. ID was curbside consulted 11/21 with recommendation to administer monoclonal antibody with Casirivimab-Imdevimab due to age >65, close contact to confirmed COVID-19 positive adult, and due to suspected
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Myalgia, Pain
Clinical narrative: On 2021-11-25 took a hike and got a little bit scratched by some grasses.  Not much tree pollen around, which I know I have been allergic to in the past, and a fair amount of flower pollen.  Started developing worrying-looking viral-shaped redness about the scratches and some itchiness.  On 2021-11-27 took another hike and this time got a bit scratched by some trees instead.  Once again, did not appear to be much tree pollen, and didn't seem to be much pollen at all around on most of the hike.  I started developing the worst, itchiest hives ever.  My skin has rash from wrist , 2-3 inches past where I got scratched, clustered around my scratches and around a tattoo from the previous Friday before the first scratch, inside the elbow, and further up the biceps clustered again around the light scratches.  I also got a few stomach scratches that look similarly worrying, viral.  I note that I have never had hives before unless counting Chicken Pox as a very small child.  This mRNA Pfizer vaccine seems to be sending my immune system into turbo mode!